The University of Turku (UTU), Finland´s second largest multidisciplinary university, is an internationally competitive research-led university whose operation is based on high-level research. University of Turku is among the top 1% in an international ranking of 20.000 universities and is ranked third best university in Finland (QS Ranking 2015). The University of Turku recognizes areas of strength in research in its strategy for 2016-2020. Our research is profiled through thematic collaborations, one of which is Drug development and Diagnostics. Our research in biosciences and medicine is at the international top of the field, which creates a strong basis for the further development of our thematic collaborations.

The research group at the Department of Molecular Biotechnology and Diagnostics (DMBM) is focused on the development of novel in vitrodiagnostic methods, analytical applications, bioaffinity assays, label technologies, recombinant proteins and genetically engineered antibodies. The laboratory is located in the premises of Turku Science Park in the brand new Medisiina D research building, with the access to the infrastructure of Biocenter Finland. Our team is an excellent blend of highly skilled experienced researchers, early stage researchers and technicians who have quest for learning and transforming the gained knowledge into practice. DMBD is an ideal place to develop and standardize novel immunoassay techniques and bioaffinity based applications due to the high quality infrastructure facilities and constant availability of resources related. From 2018, prof. Petterssons cancer diagnostics group has been a part of Cancer Research Laboratory (CRL), FICAN West, a multidisciplinary research facility combining expertise from 11 cancer research groups at UTU (IVD, Cell Biology, Systems Biology, Bioinformatics, Clinical Chemistry).